Related Experiment Video
Updated: May 30, 2026

Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm
Published on: September 17, 2021
Sublingual isosorbide dinitrate for the detection of obstruction in hypertrophic cardiomyopathy
David Zemánek1, Pavol Tomasov, Stanislava Homolová
1Department of Cardiology, University Hospital Motol, First and Second Medical School of Charles University, V Uvalu 84, 150 21 Prague, Czech Republic. zejada@seznam.cz
Insights
The isosorbide dinitrate (ISDN) spray test effectively detects left ventricular outflow tract (LVOT) obstruction in hypertrophic cardiomyopathy (HCM) patients. Optimal detection occurs 5-10 minutes post-administration, with negative tests warranting further exercise echocardiography.
Area of Science:
- Cardiology
- Cardiovascular Imaging
- Pharmacological Stress Testing
Background:
- Hypertrophic cardiomyopathy (HCM) frequently presents with left ventricular outflow tract (LVOT) obstruction.
- Provocative testing is crucial for routine HCM evaluation to assess obstruction.
- Sublingual isosorbide dinitrate (ISDN) spray is a potential agent for obstruction provocation.
Purpose of the Study:
- To evaluate the diagnostic utility of sublingual ISDN spray for detecting LVOT obstruction in HCM patients.
- To determine the optimal timing for LVOT gradient measurement after ISDN administration.
- To compare the efficacy of ISDN testing with rest and exercise echocardiography.
Main Methods:
- Prospective analysis of 77 consecutive HCM patients.
- Measurement of LVOT gradient at rest, after ISDN spray (2.5 mg at 2, 5, and 10 minutes), and during exercise echocardiography.
- Definition of obstruction as a gradient ≥ 30 mmHg.
Main Results:
- Resting LVOT obstruction was present in 19% of patients.
- ISDN testing revealed obstruction in 55% of patients, with peak detection at 5-10 minutes.
- Exercise echocardiography identified obstruction in 71% of patients.
- ISDN test demonstrated 76% sensitivity and 100% specificity compared to exercise testing.
Conclusions:
- Sublingual ISDN spray is a reliable screening tool for HCM-related LVOT obstruction.
- LVOT gradient measurement should be performed 5-10 minutes after ISDN spray application.
- Patients with a negative ISDN test result should proceed to exercise echocardiography for definitive assessment.
Aims:
Hypertrophic cardiomyopathy (HCM) is predominantly associated with left ventricular outflow tract (LVOT) obstruction. The assessment of the obstruction with a provoking test should be a routine part of HCM evaluation. The aim of the study was to determine the utility of a sublingual spray application of isosorbide dinitrate (ISDN) for detection of an obstruction.
Methods And Results:
We have prospectively analysed 77 consecutive HCM patients, measuring the LVOT gradient at rest, using the sublingual spray application of ISDN (2.5 mg; after 2, 5, and 10 min), and with exercise echocardiography. An obstruction was defined as a gradient ≥ 30 mmHg. An obstruction was present in 15 patients (19%) at rest, in 42 patients (55%) after ISDN, and in 55 patients (71%) after exercise. The ISDN test had a sensitivity of 76% and the specificity of 100% relative to exercise echocardiography, while at-rest measurements had a sensitivity of 27% and a specificity of 100%. The chronological difference in the prevalence of obstructions during the ISDN test was statistically significant (P < 0.05); at ISDN plus 2 min, obstructions were seen in only 29 patients (38%, gradient 28.8 ± 25.0 mmHg), however, at ISDN plus 5 and 10 min, obstructions were found in 42 patients (55%, gradient 44.5 ± 39.6 mmHg).
Conclusion:
The ISDN test is a reliable screening method for the detection of an HCM obstruction, however, the measurement should be delayed 5-10 min after the application of ISDN. Patients with negative ISDN tests should undergo exercise echocardiography.
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Angina II: Classification
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Antihypertensive Drugs: Vasodilators

